Business Context and Reporting Period
This Form 8-K Current Report was filed by TopSpin Medical, Inc. (a Delaware corporation) on February 2, 2010, covering events occurring on January 27 and January 28, 2010. The filing discloses the entry into a material investment agreement and a new consulting agreement.
Key Financial Metrics and Agreements
The filing details two primary financial transactions rather than standard operating metrics:
- Investment Agreement: The Company agreed to issue 211,672,857 shares of common stock, a warrant to purchase 122,935,610 shares, and a substituted warrant to purchase 58,064,516 shares to Medgenesis Partners Ltd.
- Consideration: In exchange, the Investor will pay $211,673 and cancel a previously issued warrant (the "Cancelled Warrant").
- Deposit: A non-refundable deposit of NIS 200,000 (approximately $58,000) is due on February 1, 2010.
- Consulting Agreement: The Company engaged Nichsey F.N. Fatal Ltd. for services starting March 1, 2010, at a monthly fee of NIS 34,105 (approximately $9,100).
- Equity Compensation: The Consultant will receive options to purchase 10% of the issued and outstanding shares immediately preceding issuance, subject to vesting conditions.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Conditions
The investment transaction is subject to several material conditions precedent, including:
- Approval to amend the certificate of incorporation to increase authorized capital stock.
- Approval under Section 328(b) of the Israeli Companies Law.
- Registration of shares for trade on the Tel Aviv Stock Exchange.
- Compliance with U.S. securities laws.
The agreement will terminate if not consummated or extended by June 30, 2010.
Outlook, Risks, and Contingencies
Contingencies: The issuance of consultant options is contingent upon the execution of a third-party investment or a rights offering, and the increase of registered share capital. The options vest 50% on December 17, 2010, and 50% on December 17, 2011.
Risks: The transaction involves significant dilution of existing shareholders due to the issuance of over 211 million shares and warrants for over 180 million shares. The agreement contains customary termination provisions, including termination for cause or neglect of duties.
Investor Verification Checklist
- Verify the status of the required amendment to the certificate of incorporation to increase authorized capital.
- Confirm receipt of the NIS 200,000 deposit by February 1, 2010.
- Assess the dilution impact of the 211,672,857 shares and associated warrants on current shareholders.
- Monitor the Tel Aviv Stock Exchange approval status for the new shares.
- Review the terms of the "Cancelled Warrant" to understand the full value of the consideration received.